Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

5.4K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.4K
Abnormal Proliferation02:23

Abnormal Proliferation

5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

7.9K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.9K
Tumor Progression02:07

Tumor Progression

7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
The Ras Gene02:38

The Ras Gene

7.0K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
7.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comprehensive Genomic Profiling for Precision Oncology: Analytical Validation and Clinical Utility in Solid Tumors.

Diagnostics (Basel, Switzerland)·2026
Same author

Clinical Utility of Copy Number Abnormality Analysis in the Evaluation of Melanocytic Lesions for Diagnosis and Prognosis: An Evidence-Based Review from the Cancer Genomics Consortium Working Group for Melanocytic Lesions.

Genes·2026
Same author

Real-Time Therapy Response Monitoring Using Surface Biomarkers on Circulating Tumor Cells.

Cancers·2026
Same author

Understanding Non-Small-Cell Lung Cancer: Biology, Therapeutics and Drug Resistance.

Biomedicines·2026
Same author

Brain Injury and Neurodegeneration: Molecular, Functional, and Translational Approach 3.0.

Biomedicines·2025
Same author

Oncolytic HSV-1-Mediated JAG1 Blockade Induces Glioma Senescence-Associated Secretory Phenotype to Increase Macrophage Activation and Cetuximab-Mediated Senolysis.

Cancer research·2025

Related Experiment Video

Updated: Jan 16, 2026

Induction and Analysis of Epithelial to Mesenchymal Transition
10:37

Induction and Analysis of Epithelial to Mesenchymal Transition

Published on: August 27, 2013

36.5K

TIMP-1 Modulation Correlates with KRAS Dependency and EMT Induction in NSCLC.

Ilamathi M-Thirusenthilarasan1, Pankaj Ahluwalia2, Nithyananda Thorenoor1

  • 1Department of Pathology, Penn State College of Medicine, Hershey, PA 17033, USA.

Cells
|September 26, 2025
PubMed
Summary

Tissue inhibitor of metalloproteinase-1 (TIMP-1) inversely correlates with Kirsten rat sarcoma viral oncogene homolog (KRAS) in non-small cell lung carcinoma (NSCLC). TIMP-1 modulation impacts KRAS dependency, apoptosis, and EMT, offering therapeutic insights.

Keywords:
KRASTIMP-1epithelial–mesenchymal transitionnon-small cell lung carcinomaoncogene addiction

More Related Videos

An Enzyme- and Serum-free Neural Stem Cell Culture Model for EMT Investigation Suited for Drug Discovery
07:43

An Enzyme- and Serum-free Neural Stem Cell Culture Model for EMT Investigation Suited for Drug Discovery

Published on: August 23, 2016

10.4K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

637

Related Experiment Videos

Last Updated: Jan 16, 2026

Induction and Analysis of Epithelial to Mesenchymal Transition
10:37

Induction and Analysis of Epithelial to Mesenchymal Transition

Published on: August 27, 2013

36.5K
An Enzyme- and Serum-free Neural Stem Cell Culture Model for EMT Investigation Suited for Drug Discovery
07:43

An Enzyme- and Serum-free Neural Stem Cell Culture Model for EMT Investigation Suited for Drug Discovery

Published on: August 23, 2016

10.4K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

637

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations are prevalent in human cancers, particularly non-small cell lung carcinoma (NSCLC).
  • KRAS dependency is crucial for tumor survival, but tumors can develop resistance.
  • Tissue inhibitor of metalloproteinase-1 (TIMP-1) has diverse roles beyond matrix metalloproteinase inhibition and is linked to cancer progression.

Purpose of the Study:

  • To investigate the relationship between TIMP-1 modulation and KRAS dependency in NSCLC.
  • To explore how TIMP-1 influences KRAS expression and associated cellular behaviors.
  • To elucidate potential mechanisms of therapeutic resistance in KRAS-mutated NSCLC.

Main Methods:

  • Analysis of KRAS and TIMP-1 expression in NSCLC cell lines.
  • Experimental modulation of TIMP-1 levels (overexpression and knockdown).
  • Assessment of KRAS dependency, RAS-GTP levels, apoptosis, and epithelial-mesenchymal transition (EMT) markers.
  • Bioinformatic analysis of KRAS and TIMP-1 variant-specific expression.

Main Results:

  • An inverse correlation between KRAS and TIMP-1 expression was observed in NSCLC lines.
  • TIMP-1 modulation altered KRAS levels, RAS-GTP activity, and KRAS dependency.
  • TIMP-1 overexpression reduced apoptosis in KRAS-dependent cells, while TIMP-1 knockdown increased apoptosis in KRAS-independent cells upon KRAS ablation.
  • TIMP-1 modulation affected EMT marker expression, suggesting a role in EMT induction in KRAS-independent cells.

Conclusions:

  • TIMP-1 plays a significant role in regulating KRAS dependency and tumor behavior in NSCLC.
  • TIMP-1 modulation influences critical cancer hallmarks like apoptosis and EMT.
  • Understanding the KRAS-TIMP-1 interaction may reveal novel therapeutic strategies for NSCLC.